PT - JOURNAL ARTICLE AU - Urszula Lechowicz AU - Stefan Rudziński AU - Adriana Roży AU - Joanna Chorostowska-Wynimko AU - Sabina Janciauskiene TI - Adhesion ratio of blood neutrophils from PiZZ COPD patients prior to and during augmentation treatment with alpha-1-antitrypsin AID - 10.1183/13993003.congress-2021.PA2401 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA2401 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA2401.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA2401.full SO - Eur Respir J2021 Sep 05; 58 AB - Severe alpha-1-antitrypsin (AAT) deficiency is characterized by low serum levels of AAT, high proteolytic burden, and neutrophilic inflammation in the lungs. Neutrophil adhesion plays an essential role in the inflammatory, activating selective neutrophil functions, regulating the cell response to proinflammatory mediators and neutrophil recruitment to inflamed tissue via intracellular signaling pathways. We aimed to compare blood neutrophil adhesion from healthy PiMM (normal variant) subjects vs emphysema PiZZ patients without (ZZ-BT) and with AAT augmentation therapy (ZZ-DT).Freshly isolated neutrophils were plated onto collagen-coated plates and incubated for 20 min alone or in the medium supplemented with AAT (0.1 or 4 mg/ml) or LPS (10 ng/ml). At baseline, the adhesion rate of PiMM neutrophils was 1.5-fold higher than in PiZZs. Incubation with AAT (4mg/ml) resulted in decreased neutrophil adhesion in all groups, showing 2.8 - and 4.5-fold adhesion reduction in ZZ-BT and ZZ-DT, respectively. By contrast, AAT (0.1mg/ml) stimulated PiMM neutrophil adhesion by 1.3% but reduced PiZZ-BT and PiZZ-DT neutrophil adhesion by 0.7% and 5.4 %, respectively. LPS showed no effect on neutrophil adhesion at all.Our data show that neutrophils from PiMM healthy donors have better adhesion properties than PiZZ neutrophils, independently of clinical status and AAT augmentation therapy. Remarkably, AAT seems to have concentration-dependent effects on neutrophil adhesion.This study was supported by Polish NCN Grants 2015/17/B/NZ5/01370 and 2018/29/B/NZ5/02346.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2401.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).